LIR Life Sciences

LIR Life Sciences is a Vancouver-based biotechnology company dedicated to transforming the treatment landscape for obesity and metabolic disorders through innovative, needle-free drug delivery. The company utilizes a proprietary cell-penetrating peptide (CPP) technology platform to develop transdermal patches and sublingual formulations of proven GLP-1 and GIP-based therapies. By replacing traditional injectable administration with patient-friendly formats, LIR aims to improve adherence, reduce cold-chain logistics requirements, and lower overall treatment costs. The company's lead programs are currently in the pre-clinical stage, focusing on the design and optimization of synthetic peptide variants for efficient transdermal transport. LIR Life Sciences is publicly traded and maintains strategic collaborations with contract research and manufacturing organizations to advance its pipeline toward clinical trials.